Creative Biolabs delivers biotechnology solutions to address developability liabilities in antibodies and diverse binding proteins used in discovery and preclinical research through our Phage Display for Antibody & Protein Engineering Services. High binding affinity is often only the first milestone—many candidates later show suboptimal biophysical behavior (e.g., low apparent solubility, self-association, or aggregation) that compromises expression, storage, and assay reproducibility. To mitigate these risks, we combine targeted library design with phage display selection under controlled conditions. During selection, antigen binding is maintained as the primary constraint, while additional stress conditions can be introduced as proxy filters to enrich variants with improved folding robustness and reduced developability risk. Final leads are then reformatted and expressed as recombinant proteins and evaluated using biophysical assays (e.g., SEC and thermal shift) to confirm reduced aggregation and improved stability. All deliverables are provided strictly for research use only and are not intended for clinical diagnosis, therapeutic use, or administration in humans.
In the process of developing functional proteins and research reagents, scientists frequently encounter molecular candidates that perform well in preliminary binding assays but fail during scale-up or structural validation. These failures are primarily driven by underlying biophysical liabilities. Highly hydrophobic patches on the molecular surface, unbalanced charge distributions, and suboptimal framework configurations can drastically reduce solubility. This low solubility rapidly leads to protein aggregation, particularly when the molecule is concentrated for structural studies or long-term storage.
For antibodies and fragment-based binders, aggregation and self-association can reduce the effective monomer concentration, introduce assay-to-assay variability, and in some cases increase non-specific interactions—especially in sensitive immunoassays or cell-based binding readouts. In addition, some molecules become difficult to handle at elevated concentrations due to increased viscosity or poor filterability, which complicates formulation screening and automated workflows.
Our comprehensive service portfolio provides tailored strategies to overcome severe biophysical barriers. Rather than relying on a single, one-size-fits-all methodology, we deploy a multifaceted approach to systematically improve antibody solubility by phage display and resolve intricate developability bottlenecks. Depending on the specific liability of your candidate, we customize our engineering strategies to ensure optimal results.
Whether your molecule requires subtle surface modifications or extensive framework re-engineering, our platforms are designed to enhance protein developability for research use. By integrating advanced molecular modeling with massive library screening, we deliver research-grade reagents that exhibit robust thermal stability and reduced aggregation propensity across diverse experimental conditions.
We utilize computational modeling to map surface hydrophobicity and electrostatic patches. This allows for precise, calculated amino acid substitutions that mitigate protein aggregation while minimizing perturbation to the paratope. Selected designs are subsequently verified for target binding and functional performance.
For complex liabilities, we construct focused phage display libraries with targeted diversity at developability-relevant positions (e.g., surface-exposed framework residues). This enables empirical identification of variants with improved folding robustness and reduced self-interaction propensity, which are then confirmed by recombinant expression and biophysical characterization.
We offer specialized framework shuffling, transferring binding regions onto well-characterized human frameworks that can improve overall stability and expression for certain non-human or unstable leads. Because framework changes may affect binding geometry, we incorporate binding-based selection and downstream re-validation to retain the desired specificity and affinity.
We customize our engineering approach based on the final intended molecular architecture, aiming to maintain favorable behavior upon downstream reformatting and expression. Since developability can change after reformatting (e.g., scFv to IgG/Fab), we confirm key properties after expression in the final or requested format.
To execute our engineering strategies, we employ a rigorous, systematic project workflow. This step-by-step approach seamlessly combines in silico predictability with empirical high-throughput screening to efficiently isolate variants demonstrating marked improvements in solubility and thermal stability.
The project initiates with a thorough review of the parental sequence. Using computational modeling, we assess aggregation propensity, map hydrophobic patches, and identify framework regions where mutations can be safely introduced without compromising target interaction.
We design and synthesize a custom mutant library tailored to the identified hotspots. This library is then seamlessly integrated into our optimized phage display vectors, ensuring high-efficiency expression and display of the diversified candidate pool.
Multiple rounds of biopanning are performed against the target antigen. To bias the selection toward more robust candidates, we can introduce controlled stress conditions (e.g., elevated temperature, buffer composition shifts, or increased wash stringency) prior to binding or during washing. These conditions act as proxy pressures to enrich clones that remain properly folded and binding-competent under challenge. Aggregation and solubility improvements are subsequently confirmed after recombinant expression using biophysical assays (e.g., SEC for monomer/aggregate profiling).
The enriched outputs from the biopanning rounds are screened via ELISA or similar functional assays. Positive binding clones are subsequently sequenced to determine the successful mutational patterns that confer enhanced developability.
Final candidates are expressed and subjected to rigorous in vitro profiling. We utilize analytical SEC to confirm monomeric purity and reduced aggregation, while applying thermal shift assays to quantitatively measure the achieved improvements in thermal stability.
Enhancing the biophysical properties of binding proteins unlocks their full potential in demanding research scenarios. Candidates subjected to our stability engineering protocols exhibit significantly improved shelf-lives and handling characteristics, making them exceptionally reliable as specialized assay reagents where non-specific background binding must be minimized. In the realm of structural biology, highly soluble, non-aggregating variants are frequently utilized as crystallization chaperones to assist in determining the structures of complex membrane proteins. Furthermore, for advanced molecular designs, such as components of bispecific or multivalent architectures, possessing individual modules with exceptional thermal stability and minimal protein aggregation is absolutely critical to the success and manufacturability of the final research construct.
A study published in 2022 demonstrated a practical strategy for improving binder developability by coupling phage display with a built-in thermostability filter. After an initial enrichment round, the library was routed into a dedicated “thermal branch” in which displayed binders were heat-challenged at a temperature that unfolded the parent molecule, allowing unstable variants to aggregate and be removed before binding capture. The surviving population was then recovered under higher antigen concentrations and re-selected under tighter display conditions to retain strong, monomeric binding. Importantly, the work also highlighted a common engineering lesson: variants that display well on phage may not always translate to high soluble expression without downstream reformatting and confirmation.
Fig.1 Thermostability-guided phage display selection workflow showing heat challenge, enrichment, and screening steps that enrich binding-competent, more robust variants. 1
These results support a publishable rationale for solubility/stability improvement campaigns: maintain target binding as the primary constraint, apply controlled stress as a proxy pressure to enrich folding-robust clones, and then validate improvements after recombinant expression using quantitative biophysical readouts. In practice, this means pairing selection with post-selection characterization (e.g., melting temperature measurements and aggregation/monomer profiling by SEC) and, when needed, combining mutations that independently improve binding and robustness. This “select under challenge, then verify in the final format” workflow reduces the risk of advancing candidates that bind well but fail later due to instability, self-association, or aggregation.
Q: What causes poor solubility and protein aggregation in my candidates?
Q: How does phage display improve thermal stability?
A: We create a focused mutant library and keep antigen binding as the primary selection constraint. By introducing controlled stress (e.g., heat or buffer challenges) before binding and/or increasing wash stringency, variants that remain folded and binding-competent under challenge are preferentially enriched. The resulting leads are then expressed as recombinant proteins and characterized (e.g., thermal shift assays) to quantitatively confirm improvements in thermal stability.
Q: Will modifying the sequence to improve solubility reduce the binding affinity?
A: By prioritizing framework or surface-exposed residues away from key paratope contacts—and by maintaining binding-based selection during panning—we often improve solubility-related liabilities while minimizing affinity loss. However, because trade-offs can occur, we re-verify binding affinity/kinetics on the expressed variants.
Q: How do you confirm that protein aggregation has been reduced?
A: We utilize rigorous in vitro analytical methods. Following selection, the purified variants are analyzed using Size Exclusion Chromatography (SEC) to quantify the monomeric fraction and verify the absence of high-molecular-weight aggregates. We also employ thermal shift assays to confirm improvements in thermal stability.
Q: What types of molecules can benefit from this stability engineering?
A: This approach is highly effective for scFv fragments, Fab fragments, VHH domains (camelid single-domain binding proteins), and various other engineered protein scaffolds that exhibit aggregation tendencies or require enhanced developability for complex research applications.
Q: Are the engineered proteins suitable for clinical therapeutic use?
A: No. All proteins and variant libraries engineered through our solubility and developability enhancement services are provided strictly for research use only (RUO). They are not intended for, nor approved for, clinical diagnosis, therapeutic administration, or any use in humans.
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
